Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa in Anemic Low Risk MDS
NCT00095264Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
A Phase 2 trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Amgen. Started Oct 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00095264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095264.